A business-unit sponsor is not being asked for capital. They are being asked to commit operational attention against a technology that may not work, on a timeline they do not control. Evidence that their own customers want it moves that conversation; evidence that the market is growing does not.
Why does the second approval stall?
Because the two approvers are being asked different questions and shown the same deck. The fund's committee is assessing an investment; the business unit is assessing a commitment of its own people's time.
A market-growth case answers the first and is irrelevant to the second, and its prominence in the materials frequently signals that the second test was never scoped.
The single-deck habit is the root of it. One set of materials is prepared for the fund, reviewed by the fund, and then shown to a business unit as though the audience had not changed. Producing a second, shorter document that answers only the adoption question is a small amount of work and it is the intervention that most reliably unsticks these processes.
| Fund committee | Business-unit sponsor | |
|---|---|---|
| Assessing | Whether the investment returns | Whether their team will use it |
| Persuaded by | Market growth and comparable exits | Their own customers asking for it |
| Risk carried | Capital | Attention, credibility and their own targets |
What is a sponsor risking?
Attention, credibility and delivery against their own targets. Sponsoring a technology that does not work costs them more than it costs the fund, and they know that.
That asymmetry is rational and it is usually treated as obstruction, which is why these conversations go badly more often than they need to.
The sponsor's exposure is also asymmetric in time. The fund's return arrives years later and is judged against a portfolio; the sponsor's commitment shows up in this year's operating plan and is judged on its own. That difference in horizon explains most of what looks like reluctance, and it is not addressed by anything in a return case.
What evidence changes their mind?
That their own customers want it. Interviews with the sponsor's customer base carry weight no market forecast can, because they speak directly to the risk the sponsor is personally carrying.
Evidence from adjacent adopters — companies like theirs that have deployed similar technology — is the second most persuasive, and for the same reason.
Adjacent-adopter evidence has a further advantage: it is available even where the sponsor's own customers cannot be approached. Companies of comparable size in a comparable position that have deployed the technology can describe what implementation actually required, which is the specific thing a sponsor is trying to estimate and the thing a vendor reference will not tell them.
When should you gather it?
Before the fund approval, not after. Going back to a sponsor who has already declined once is a materially harder conversation than the first, and the decline hardens quickly.
It also improves the fund case. Evidence of adoption intent is a return argument as well as a strategic one — provided it is read as a ranking rather than a rate.
There is a sequencing benefit inside the fund process too. Adoption evidence gathered early tends to sharpen the commercial case, because the questions that establish whether a business unit would use something are the same questions that establish whether anyone would. Teams that run it early report a better fund case rather than merely a faster second approval.
What happens after the investment?
Whatever was implied. If the deal was approved on the basis that the business unit would pilot the technology, that obligation should be written down at approval rather than assumed.
Without it, the investment quietly becomes financial-only, which is usually a worse version of what a pure venture investor would have done.